Sumitomo Life Insurance Co. Has $1.95 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Sumitomo Life Insurance Co. cut its stake in IQVIA Holdings Inc. (NYSE:IQV) by 1.6% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 9,904 shares of the medical research company’s stock after selling 164 shares during the quarter. Sumitomo Life Insurance Co.’s holdings in IQVIA were worth $1,946,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of IQV. Capital Performance Advisors LLP bought a new position in shares of IQVIA during the third quarter valued at $27,000. Park Place Capital Corp acquired a new stake in shares of IQVIA during the 3rd quarter worth about $28,000. Avior Wealth Management LLC boosted its position in IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares in the last quarter. Assetmark Inc. grew its stake in IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after buying an additional 196 shares during the last quarter. Finally, UMB Bank n.a. increased its holdings in shares of IQVIA by 74.4% during the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after buying an additional 99 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV stock opened at $197.90 on Thursday. The stock has a market cap of $35.92 billion, a PE ratio of 25.97, a price-to-earnings-growth ratio of 2.14 and a beta of 1.48. The stock has a 50-day moving average of $200.27 and a 200-day moving average of $220.95. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Leerink Partners reissued an “outperform” rating and issued a $248.00 target price (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. The Goldman Sachs Group decreased their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. BTIG Research reduced their price target on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Barclays lowered their price objective on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Finally, TD Cowen reduced their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $255.71.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.